BRIEF published on 08/06/2024 at 18:44, 1 month 13 days ago Funding Circle Plc : Transaction POS en actions propres Rachat D'actions Bourse Numis Securities Actualités Financières Cercle De Financement
BRIEF published on 08/06/2024 at 18:44, 1 month 13 days ago Funding Circle Plc: POS-Transaction in Own Shares Share Buyback Financial News Stock Market Numis Securities Funding Circle
PRESS RELEASE published on 08/06/2024 at 18:39, 1 month 13 days ago Funding Circle Plc: POS-Transaction in Own Shares Funding Circle Plc announces the purchase and cancellation of 262,130 ordinary shares at prices ranging from 95.20p to 101.50p per share London Stock Exchange Ordinary Shares Share Buyback Cancellation Funding Circle Plc
BRIEF published on 08/05/2024 at 18:41, 1 month 14 days ago Funding Circle Plc annonce le rachat et l'annulation d'actions Rachat D'actions Numis Securities Bourse De Londres Cercle De Financement Annulation De Partage
BRIEF published on 08/05/2024 at 18:41, 1 month 14 days ago Funding Circle Plc Announces Share Buyback and Cancellation London Stock Exchange Share Buyback Numis Securities Share Cancellation Funding Circle
PRESS RELEASE published on 08/05/2024 at 18:36, 1 month 14 days ago Funding Circle Plc: POS-Transaction in Own Shares Funding Circle Plc announces purchase of 485,682 ordinary shares for cancellation on the London Stock Exchange. Shares were bought back at prices ranging from 92.40p to 99.00p London Stock Exchange Share Purchase Cancellation Funding Circle Plc Buy-back
BRIEF published on 08/02/2024 at 18:20, 1 month 17 days ago Funding Circle Plc Executes Share Buyback Share Buyback Regulation (EU) No 596/2014 Numis Securities Capital Structure Funding Circle
BRIEF published on 08/02/2024 at 18:20, 1 month 17 days ago Funding Circle Plc exécute un rachat d'actions Rachat D'actions Numis Securities Cercle De Financement La Structure Du Capital Règlement (UE) N° 596/2014
PRESS RELEASE published on 08/02/2024 at 18:15, 1 month 17 days ago Funding Circle Plc: POS-Transaction in Own Shares Funding Circle Plc announces cancellation of 459,847 ordinary shares purchased in buy-back program. Share capital to be 342,537,443 with voting rights Share Capital London Stock Exchange Buy-back Program Cancellation Funding Circle Plc
BRIEF published on 08/01/2024 at 18:12, 1 month 18 days ago Funding Circle Plc Executes Share Buyback Program Ordinary Shares Share Buyback Numis Securities Market Regulation Funding Circle
Published on 09/20/2024 at 15:00, 1 hour 55 minutes ago DISCOVER FH Collaboration With Family Heart Foundation, UT Southwestern, and Partners
Published on 09/20/2024 at 15:00, 1 hour 55 minutes ago Tacora Resources Inc. completes CCAA Sale Transaction, Emerging with a Strengthened Balance Sheet, Renewed Conviction on High-Grade Iron Ore, and a Plan to Realize Production Growth
Published on 09/20/2024 at 14:30, 2 hours 25 minutes ago Focus Universal Inc. Announces Listing Transfer to Nasdaq Capital Market
Published on 09/20/2024 at 14:00, 2 hours 55 minutes ago Scepter Files Form 10 with SEC Paving the Way for Strategic Growth
Published on 09/20/2024 at 14:00, 2 hours 55 minutes ago Tectonic Metals Announces Results Of 2024 Annual General Meeting
Published on 09/20/2024 at 15:29, 1 hour 25 minutes ago Just – Evotec Biologics opens cutting-edge biologics facility - J.POD® Toulouse, France (EU)
Published on 09/20/2024 at 15:14, 1 hour 40 minutes ago a sknet becomes part of Academic Software Resulting in a powerful combination of two leaders in digital education.
Published on 09/20/2024 at 14:59, 1 hour 55 minutes ago Form 8.3 - The Vanguard Group, Inc.: Darktrace plc
Published on 09/20/2024 at 14:58, 1 hour 56 minutes ago Form 8.3 - The Vanguard Group, Inc.: International Distribution Services plc
Published on 09/20/2024 at 14:57, 1 hour 58 minutes ago Form 8.3 - The Vanguard Group, Inc.: SEGRO plc
Published on 09/20/2024 at 08:45, 8 hours 10 minutes ago BAIKOWSKI : Rapport financier semestriel 2024
Published on 09/20/2024 at 08:00, 8 hours 55 minutes ago MEDESIS PHARMA : Résultats encourageants de la première phase de l’essai clinique de phase 2a pour le traitement de la maladie d’Alzheimer avec le NanoLIthium